💊
Conbriza
bazedoxifene
Osteoporosis, posmenopáusica
✅ Autorizado
✅
No hay alertas activas
Este medicamento no tiene escasez en curso, cartas de seguridad ni retiradas del mercado.
Para qué se utiliza
Conbriza is indicated for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. A significant reduction in the incidence of vertebral fractures has been demonstrated; efficacy on hip fractures has not been established. When determining the choice of Conbriza or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits.
⚠️ Seguridad del paciente
No
Página oficial de la EMA
https://www.ema.europa.eu/en/medicines/human/EPAR/conbriza